Stanford Neuroscience Health Center
Stanford, California, 94305, United States
Location status: Recruiting
NCT Number: NCT05968703
The goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM) to treat cognitive and cognitive-motor symptoms in individuals with Parkinson's disease. The main question it aims to answer is:
Is a combined deep brain stimulation approach targeting the STN and NBM with four DBS leads safe and tolerable for cognitive and cognitive-motor symptoms in individuals with Parkinson's disease with Mild Cognitive Impairment. Ten participants are anticipated to be enrolled.
Participants will undergo a modification of the traditional STN DBS approach for motor symptoms of PD. In addition to the two leads placed within the STN, two additional leads will be placed with the NBM for treatment of cognitive and cognitive-motor symptoms. Novel stimulation patterns will be used within the NBM to target cognitive and cognitive-motor symptoms using an investigational software. Participants will be followed over two years while receiving this therapy with assessments at baseline and every six months. Assessments will include a combination of neuropsychological evaluations, cognitive assessments, motor tasks (including gait/walking), and questionnaires to evaluate the treatment. Two different surgical trajectories will be used, with half the cohort randomized to each group. This will allow comparison of the impact of surgical trajectory on the intervention.
Interested in participating?
Request Info21 year–80 year
All sexes
Interventional
Not applicable
Stanford, California, 94305, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This intervention is a 4-lead deep brain stimulation approach targeting the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM)
Time frame: From baseline to 1 year into treatment
Any untoward medical occurrence that occurs during this study whether or not considered related to the study device, study procedures, or study requirements that is identified or worsens during the duration of the study
Time frame: From baseline to 1 year into treatment
Swing time variability will be measured using the dual force plates in the SIP task and IMUs for TBC. It is defined as the mean swing time coefficient of variation (CV) of both legs.
Time frame: From baseline to 1 year into treatment
Duration of freezing episodes during SIP will be measured using IMUs and force plates using a validated offline algorithm.
Time frame: From baseline to 1 year into treatment
Stride time coefficient of variation will be measured using the dual force plates in the SIP task and IMUs. Stride time coefficient of variation is defined as the mean stride time coefficient of variation (CV) of both legs. A greater stride time CV is indicative of less rhythmic gait/stepping.
Time frame: From baseline to 1 year into treatment
Shank angular velocity will be measured from IMUs work on the participant's leg/ankle. Reductions in this value are indicative of FOG and gait impairment.
Time frame: From baseline to 1 year into treatment
The interstrike-interval of alternating tapping will be measured using an engineered piano keyboard. A higher interstrike-interval indicates slower tapping
Time frame: From baseline to 1 year into treatment
The variability of the interstrike-interval of alternating tapping, as quantified by the coefficient of variation, will be measured using an engineered piano keyboard. A higher coefficient of variation indicates worse rhythmicity
Time frame: From baseline to 1 year into treatment
PD symptoms will be assessed clinically using the MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Section III. This is a motor examination to evaluate speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movement of hands, leg agility, arising from chair, posture, gait, freezing of gait, posture, body bradykinesia, and postural stability. Each item is scored on a scale from 0 (normal) to 4 (severe), with the total possible score ranging from 0 to 132.
Time frame: From baseline to 1 year into treatment
Each trial of the SAT will be categorized as a Hit (H), Miss (M), or False Alarm (FA). The SAT score is defined as ((H - FA) / [2× (H + FA) - (H + FA)2]), which ranges from - 1.0 (100% incorrect performance; all misses and false alarms) to +1.0 (100% correct performance; all hits and correct rejections).
Time frame: From baseline to 1 year into treatment
The percent of false positives during the SAT.
Time frame: From baseline to 1 year into treatment
The percent of misses of total trials during the SAT
Time frame: From baseline to 1 year into treatment
The average and standard deviation of the response time during the SAT.
Time frame: From baseline to 1 year into treatment
Hit rate during the first minute in the no- distractor condition for the CTET.
Time frame: From baseline to 1 year into treatment
Hit rate change slope in no-distractor condition for the CTET.
Time frame: From baseline to 1 year into treatment
Hit rate difference between no-distractor and distractor conditions for the CTET.
Time frame: From baseline to 1 year into treatment
Cognitive scale composed of 9 tasks that assesses the full range of cognitive dysfunction in PD. It is a scale of 0 to 134, with 134 being the best score.
Time frame: From baseline to 1 year into treatment
Total score to assess of this rapid screening test of different cognitive domains. It is a scale of 0 to 30, with 30 being the best score.
Time frame: From baseline to 1 year into treatment
The time it takes to complete the task and errors.
Time frame: From baseline to 1 year into treatment
The time it takes to complete the task and errors.
Time frame: From baseline to 1 year into treatment
The summation of the number of correct substitutions within the 90 second interval.
Time frame: From baseline to 1 year into treatment
Percentile of performance on visual puzzles for participant's demographic.
Time frame: From baseline to 1 year into treatment
Percentile of performance on judgement of line orientation for participant's demographic.
Time frame: From baseline to 1 year into treatment
Total score on questionnaire regarding participant's mood the last 2 weeks. The scale ranges from 0 to 27 with a score of 27 indicating the most severe symptoms.
Time frame: From baseline to 1 year into treatment
Total score on questionnaire regarding participant's anxiety the last two weeks.The scale ranges from 0 to 21 with a score of 21 indicating the most severe symptoms.
Time frame: From baseline to 1 year into treatment
Total score evaluating the non-motor aspects of experiences of daily living. It is a scale from 0 to 52 with 52 being the most severe symptoms.
Time frame: From baseline to 1 year into treatment
Total score evaluating the motor aspects of experiences of daily living. It is a scale from 0 to 52 with 52 being the most severe symptoms.
Time frame: From baseline to 1 year into treatment
Total score of motor complications experienced by the participant. It is a scale from 0 to 24 with 24 being the most severe symptoms.
Time frame: From baseline to 1 year into treatment
Total score for symptom severity and distress via questionnaire. It is a scale from 0 to 60 with 60 indicating worse symptoms.
Time frame: From baseline to 1 year into treatment
Total score for Parkinson's disease-specific health related quality over the last month across 8 quality of life dimensions assessed via questionnaire. Score ranges from 0 to 100 with 100 indicating more symptoms and problems.
Time frame: From baseline to 1 year into treatment
Total score on caregiver self-report to assess the stress-levels of family caregivers. It is a scale from 0 to 88 with higher scores indicating greater or worse burden.
Contact information is provided by the study sponsor or research team.
Helen M. Bronte-Stewart
Other
Neurostimulation of the Nucleus Basalis of Meynert for the Cognitive-Motor Syndrome in Parkinson's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04396873
ALS, Alzheimer Disease
Bethesda, Maryland, United States
View Trial DetailsNCT07441915
Basal Ganglia Diseases, Brain Diseases
Zurich, Canton of Zurich, Switzerland
View Trial DetailsNCT03836950
Basal Ganglia Diseases, Brain Diseases
Chicago, Illinois, United States
View Trial DetailsNCT03233646
APOE-4 Positive, Abnormalities, Multiple
Durham, North Carolina, United States
View Trial Details